Tyrosine kinase inhibitors interstitial pneumonitis: diagnosis and management

被引：13
作者：
He, Yayi [1 ]
Zhou, Caicun [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Canc Inst,Dept Med Oncol, 507 Zhengmin Rd, Shanghai 200433, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2019年 / 8卷
基金：
中国国家自然科学基金;
关键词：
LUNG-CANCER PATIENTS; OPEN-LABEL; 1ST-LINE TREATMENT; DISEASE; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB; GEFITINIB; OSIMERTINIB; CISPLATIN;
D O I：
10.21037/tlcr.2019.05.02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S318 / S320
页数：3
相关论文
共 27 条
[1]   Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib [J].
Ando, M ;
Okamoto, I ;
Yamamoto, N ;
Takeda, K ;
Tamura, K ;
Seto, T ;
Ariyoshi, Y ;
Fukuoka, M .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2549-2556
[2]   New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer [J].
Cameron, Laird ;
Solomon, Benjamin .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (10)
[3]   Acquired resistance to TKIs in solid tumours: learning from lung cancer [J].
Camidge, D. Ross ;
Pao, William ;
Sequist, Lecia V. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (08) :473-481
[4]   Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].
Camidge, D. Ross ;
Bang, Yung-Jue ;
Kwak, Eunice L. ;
Iafrate, A. John ;
Varella-Garcia, Marileila ;
Fox, Stephen B. ;
Riely, Gregory J. ;
Solomon, Benjamin ;
Ou, Sai-Hong I. ;
Kim, Dong-Wan ;
Salgia, Ravi ;
Fidias, Panagiotis ;
Engelman, Jeffrey A. ;
Gandhi, Leena ;
Jaenne, Pasi A. ;
Costa, Daniel B. ;
Shapiro, Geoffrey I. ;
LoRusso, Patricia ;
Ruffner, Katherine ;
Stephenson, Patricia ;
Tang, Yiyun ;
Wilner, Keith ;
Clark, Jeffrey W. ;
Shaw, Alice T. .
LANCET ONCOLOGY, 2012, 13 (10) :1011-1019
[5]   Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer [J].
Chiang, Chi-Lu ;
Chen, Yi-Wei ;
Wu, Mei-Han ;
Huang, Hsu-Ching ;
Tsai, Chun-Ming ;
Chiu, Chao-Hua .
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2016, 79 (05) :248-255
[6]   Understanding, recognizing, and managing toxicities of targeted anticancer therapies [J].
Dy, Grace K. ;
Adjei, Alex A. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (04) :249-279
[7]   Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: An analysis of risk factors and treatment outcomes in Okayama lung cancer study group [J].
Hotta, K ;
Kiura, K ;
Tabata, M ;
Harita, S ;
Gemba, K ;
Yonei, T ;
Bessho, A ;
Maeda, T ;
Moritaka, T ;
Shibayama, T ;
Matsuo, K ;
Kato, K ;
Kanehiro, A ;
Tanimoto, Y ;
Matsuo, K ;
Ueoka, H ;
Tanimoto, M .
CANCER JOURNAL, 2005, 11 (05) :417-424
[8]   Severe acute interstitial pneumonia and gefitinib [J].
Inoue, A ;
Saijo, Y ;
Maemondo, M ;
Gomi, K ;
Tokue, Y ;
Kimura, Y ;
Ebina, M ;
Kikuchi, T ;
Moriya, T ;
Nukiwa, T .
LANCET, 2003, 361 (9352) :137-139
[9]   Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation [J].
Inoue, Akira ;
Xin, Hong ;
Suzuki, Takuji ;
Kanehira, Masahiko ;
Kuroki, Yoshio ;
Fukuhara, Tatsuro ;
Kikuchi, Toshiaki ;
Maemondo, Makoto ;
Nukiwa, Toshihiro ;
Saijo, Yasuo .
CANCER SCIENCE, 2008, 99 (08) :1679-1684
[10]   Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Up-regulates Interleukin-6 in Cancer Cells and Induces Subsequent Development of Interstitial Pneumonia [J].
Ishiguro, Yukari ;
Ishiguro, Hitoshi ;
Miyamoto, Hiroshi .
ONCOTARGET, 2013, 4 (04) :550-559
123